415 related articles for article (PubMed ID: 25337775)
21. Spironolactone decreases the somatic signs of opiate withdrawal by blocking the mineralocorticoid receptors (MR).
Navarro-Zaragoza J; Laorden ML; Milanés MV
Toxicology; 2014 Dec; 326():36-43. PubMed ID: 25308750
[TBL] [Abstract][Full Text] [Related]
22. Structural, functional, and molecular alterations produced by aldosterone plus salt in rat heart: association with enhanced serum and glucocorticoid-regulated kinase-1 expression.
Martín-Fernández B; de las Heras N; Miana M; Ballesteros S; Delgado C; Song S; Hintze T; Cachofeiro V; Lahera V
J Cardiovasc Pharmacol; 2011 Jan; 57(1):114-21. PubMed ID: 20980916
[TBL] [Abstract][Full Text] [Related]
23. Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress.
Nagase M; Matsui H; Shibata S; Gotoda T; Fujita T
Hypertension; 2007 Nov; 50(5):877-83. PubMed ID: 17875821
[TBL] [Abstract][Full Text] [Related]
24. Spironolactone improves angiotensin-induced vascular changes and oxidative stress.
Virdis A; Neves MF; Amiri F; Viel E; Touyz RM; Schiffrin EL
Hypertension; 2002 Oct; 40(4):504-10. PubMed ID: 12364354
[TBL] [Abstract][Full Text] [Related]
25. Protective effects of spironolactone on vascular calcification in chronic kidney disease.
Hammer F; Buehling SS; Masyout J; Malzahn U; Hauser T; Auer T; Grebe S; Feger M; Tuffaha R; Degenhart G; Lang F; Pasch A; Alesutan I; Wanner C; Krane V; Voelkl J
Biochem Biophys Res Commun; 2021 Dec; 582():28-34. PubMed ID: 34678593
[TBL] [Abstract][Full Text] [Related]
26. The effects of aldosterone on diet-induced fatty liver formation in male C57BL/6 mice: comparison of adrenalectomy and mineralocorticoid receptor blocker.
Gamliel-Lazarovich A; Raz-Pasteur A; Coleman R; Keidar S
Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1086-92. PubMed ID: 23524523
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.
Arai K; Homma T; Morikawa Y; Ubukata N; Tsuruoka H; Aoki K; Ishikawa H; Mizuno M; Sada T
Eur J Pharmacol; 2015 Aug; 761():226-34. PubMed ID: 26073023
[TBL] [Abstract][Full Text] [Related]
28. Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes.
Amador CA; Barrientos V; Peña J; Herrada AA; González M; Valdés S; Carrasco L; Alzamora R; Figueroa F; Kalergis AM; Michea L
Hypertension; 2014 Apr; 63(4):797-803. PubMed ID: 24420551
[TBL] [Abstract][Full Text] [Related]
29. Biotransformation of the mineralocorticoid receptor antagonists spironolactone and canrenone by human CYP11B1 and CYP11B2: Characterization of the products and their influence on mineralocorticoid receptor transactivation.
Schiffer L; Müller AR; Hobler A; Brixius-Anderko S; Zapp J; Hannemann F; Bernhardt R
J Steroid Biochem Mol Biol; 2016 Oct; 163():68-76. PubMed ID: 27125452
[TBL] [Abstract][Full Text] [Related]
30. Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury.
Luther JM; Luo P; Wang Z; Cohen SE; Kim HS; Fogo AB; Brown NJ
Kidney Int; 2012 Sep; 82(6):643-51. PubMed ID: 22622494
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of mineralocorticoid receptors with eplerenone alleviates short-term cyclosporin A nephrotoxicity in conscious rats.
Nielsen FT; Jensen BL; Marcussen N; Skøtt O; Bie P
Nephrol Dial Transplant; 2008 Sep; 23(9):2777-83. PubMed ID: 18424460
[TBL] [Abstract][Full Text] [Related]
32. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction.
Mihailidou AS; Loan Le TY; Mardini M; Funder JW
Hypertension; 2009 Dec; 54(6):1306-12. PubMed ID: 19841288
[TBL] [Abstract][Full Text] [Related]
33. (Pro)Renin receptor regulates potassium homeostasis through a local mechanism.
Xu C; Lu A; Wang H; Fang H; Zhou L; Sun P; Yang T
Am J Physiol Renal Physiol; 2017 Sep; 313(3):F641-F656. PubMed ID: 27440776
[TBL] [Abstract][Full Text] [Related]
34. Aldosterone induces elastin production in cardiac fibroblasts through activation of insulin-like growth factor-I receptors in a mineralocorticoid receptor-independent manner.
Bunda S; Liu P; Wang Y; Liu K; Hinek A
Am J Pathol; 2007 Sep; 171(3):809-19. PubMed ID: 17724138
[TBL] [Abstract][Full Text] [Related]
35. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo.
Brown NJ; Nakamura S; Ma L; Nakamura I; Donnert E; Freeman M; Vaughan DE; Fogo AB
Kidney Int; 2000 Sep; 58(3):1219-27. PubMed ID: 10972684
[TBL] [Abstract][Full Text] [Related]
36. Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism.
Luther JM; Gainer JV; Murphey LJ; Yu C; Vaughan DE; Morrow JD; Brown NJ
Hypertension; 2006 Dec; 48(6):1050-7. PubMed ID: 17043157
[TBL] [Abstract][Full Text] [Related]
37. Role of mineralocorticoid receptor on experimental cerebral aneurysms in rats.
Tada Y; Kitazato KT; Tamura T; Yagi K; Shimada K; Kinouchi T; Satomi J; Nagahiro S
Hypertension; 2009 Sep; 54(3):552-7. PubMed ID: 19620512
[TBL] [Abstract][Full Text] [Related]
38. Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury.
Barrera-Chimal J; Pérez-Villalva R; Rodríguez-Romo R; Reyna J; Uribe N; Gamba G; Bobadilla NA
Kidney Int; 2013 Jan; 83(1):93-103. PubMed ID: 23014458
[TBL] [Abstract][Full Text] [Related]
39. Mineralocorticoid receptor antagonist spironolactone prevents pig serum-induced hepatic fibrosis in rats.
Fujisawa G; Muto S; Okada K; Kusano E; Ishibashi S
Transl Res; 2006 Sep; 148(3):149-56. PubMed ID: 16938653
[TBL] [Abstract][Full Text] [Related]
40. Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology.
Wilkinson-Berka JL; Tan G; Jaworski K; Harbig J; Miller AG
Circ Res; 2009 Jan; 104(1):124-33. PubMed ID: 19038868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
